Treating nicotine addiction with glucagon-like peptide 1 receptor agonists is associated with less weight gain compared with ...

GLP-1 agonists may help reduce acetazolamide dosage in patients with idiopathic intracranial hypertension without changing clinical outcome.

As Australia faces a turning point in obesity management, researchers from Monash University have contributed new insights ...

New review confirms psychiatric safety of commonly used glucagon-like peptide 1 receptor agonists among patients without ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may cut the risk of obesity-related cancer (ORC) in patients being treated for diabetes and obesity.

A new meta-analysis presented at APA 2025 reveals that GLP-1 receptor agonists may help smokers manage post-cessation weight ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can lead to significant weight loss and improve blood sugar control in ...

GLP-1 receptor agonists are associated with improvements in restrained eating, emotional eating behavior, QOL.

Risks for prostate cancer metastasis or death appeared lower with GLP-1 RA use compared with use of other antidiabetic drugs. Patients with prostate cancer who take glucagon-like peptide-1 ...

GLP-1 RAs are associated with a significant decrease in apnea-hypopnea index among patients with moderate to severe OSA and without diabetes.